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accelerator. For these patients, the 3D intra-treatment 
tumor motion was measured with a sampling frequency of 5-
8Hz by intra-treatment x-ray imaging of implanted gold 
markers. The dosimetric effect of this motion on the proton 
plans was investigated as follows. The proton plans were 
dicom exported from the TPS (Eclipse, Varian Medical 
Systems) and manipulated by an in-house developed 
computer program that simulated the proton delivery using 
realistic spot dynamics. The program incorporated the tumor 
motion into the treatment plans by shifting each proton spot 
to its position as seen in tumor’s eye view. Depth motion and 
variations in source-surface-distances were simulated by 
modifying the beam energy. The motion encoded plans were 
re-imported into the TPS, where dose calculation resulted in 
the motion including tumor dose. Treatments with both 
cranio-caudal and lateral beam scan direction and with 1, 2, 
4, 6, and 10 (volumetric) paintings were simulated. The 
simulations and dose reconstruction have so far been 
performed for 4 of the 16 patients (3 fractions and 60 
simulated treatments per patient) with relatively large and 
irregular tumor motion. For each treatment, the dosimetric 
impact of interplay effects was quantified as D5-D95 for the 
GTV. 
Results: The figure shows the mean D5-D95 as function of the 
number of paintings for the four simulated scenarios. For 
some cases, the reduction in interplay effects with increased 
repainting tended to be less monotonous for IMPT than for 
SFO, which is reflected by the larger standard variations in 
D5-D95 for IMPT (see figure). No systematic effect of the scan 
direction was observed.  
 
Conclusions: A method to investigate the dosimetric impact 
of tumor motion during proton spot scanning in a commercial 
TPS was developed and applied for liver SBRT treatments 
using patient-measured intra-treatment tumor motion. The 
simulations are currently being extended to all 16 patients in 
the motion database as well as to gated treatments 
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Purpose/Objective: The first MLC tracking clinical 
treatments have been performed for a prospective prostate 
clinical trial. The aim of this study is to assess whether MLC 
tracking improves the agreement between the planned and 
delivered doses for prostate cancer radiotherapy compared 
to standard no tracking treatment delivery. 
Materials and Methods: MLC tracking has been implemented 
in a 30 patient prostate cancer radiotherapy trial, to date 18 
patients have been treated and 603 treatment fractions 
delivered. The prostate trajectory and treatment MLC 
positions were collected during each fraction and the data 
used as input for dose reconstruction (isocenter shift 
method). The treated dose (with MLC tracking) and the dose 
that would have been delivered had MLC tracking not been 
implemented were both reconstructed. The percentage 
difference from planned for PTV, CTV, rectum and bladder 
dose-volume points were calculated for each individual 
treatment fraction. For each dose-volume value analysis of 
variance using the F-test was used to test whether MLC 
tracking improves the consistency between the planned and 
treated MLC tracking values over that of no MLC tracking. 
The effect of planning parameters including, collimator 
angle, complexity (MU/Gy), the homogeneity index and the 
conformity index of the dose to the target on the dose 
delivery were also investigated. 
Results: The results for the first ten patients showed that the 
average mean prostate motion during beam-on for a total of 
292 2 Gy fractions was 1.3 mm, with 96% of fractions having a 
mean displacement of <2.5 mm. The mean difference and 
standard deviation between the planned and treated MLC 
tracking doses, and the planned and no MLC tracking doses 
for 260 fractions of 2 Gy were respectively: PTV D99% -
0.8±1.0% vs. -1.9±2.4%; CTV D99% -0.6±0.8% vs. -0.6±1.2%; 
rectum V65% 1.8±6.8% vs. -0.5±17%; and bladder V65% 0.1±3.5% 
vs. -0.4±7.4% (p<0.001 for all dose-volume results). The 
percentage differences for the all of individual fractions can 
be seen in Fig 1. No correlation between the planning 
parameters and the effectiveness of MLC tracking treatments 
(percentage difference from planned) were found. 
 
 
Fig. 1 The calculated percentage dose difference (for 260 
fractions of 2 Gy) from the planned value for the treated 
(blue) and no MLC tracking (red) dose distributions for PTV 
and CTV D99% values, represented by median, 25th and 75th 
percentile. Vertical lines indicate the maximum and 
minimum values. 
Conclusions: The results of this study show that improved 
consistency between the planned and delivered doses is 
obtain when implementing MLC tracking compared to doses 
that would have been delivered without MLC tracking.  
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